get ready to attend asia’s biggest leadership …pharmaleaders2017.com/downloads/6th-annual...6 th...

6th

PharmaceuticalPharmaceuticalLeadership Summit

20132013TM

Annual

Pharmaceutical Leadership Summit &

Business Leadership Awards 20136th

An

nu

al

GET READY TO ATTEND ASIA’SBIGGEST LEADERSHIP EXPERIENCE IN HEALTH CARE

Developed by6th


20132013TM

Annual

6th ANNUAL PHARMACEUTICAL LEADERSHIP SUMMIT & BUSINESS LEADERSHIP AWARDS 2013

INCREDIBLE PHARMALEADERS 2013BILLION DREAMS-PUSHING INDIA'S GROWTH AGENDA

Friday,27st December 2013 ,Hotel Hilton, Mumbai Intercontinental, Airport,Mumbai,India

POWER

Pharma Leaders

2013

Pharma Leaders

2013

BRAND

CeleExceHealInnoSince

brating llence in thcare vations 1999

INCRED BLE

PUSHING INDIA’S GROWTH AGENDAPUSHING INDIA’S INDIA’S GROWTH AGENDAFriday, 27th December, 2013, Hotel Hilton, Mumbai International Airport, India

BILLION DREAMS

Satya BrahmaChairman & Editor -in-Chief-Pharmaleaders

DearColleague...

6th


20132013TM

Annual

India's pharma market has evolved and shifted gears to set foot on an accelerated growth path. In conclusion, as emerging markets become increasingly important and India's role among these becomes progressively significant, both domestic and pharma MNCs will need to adapt their business models, organisations and processes and create customised strategies.

Overall, active participation from domestic and international pharma companies, increased investments and strategic initiatives will likely underpin future growth and enable the Indian pharma market to break into the global top tier in the present decade.

ICRA expects 10-12% growth for pharma industry in 2013-14 ICRA has come out with industry update release on pharma sector. The research firm, expects the industry to revert to a growth of 10-12% in 2013-14. The impact of new DPCO though expected to be limited, could also get offset by volume expansion and efforts of industry participants to take price hike in rest of the portfolio.Growth opportunities intact but managing industry challenges remains key for Indian Pharmaceutical Industry: ICRA Despite the high-base of the previous year, ICRA believes that the Indian Pharmaceutical industry would continue to experience strong growth in the near- term however there would some moderation in the growth trajectory. Principally, the generic opportunities in US will continue to drive revenue growth for Indian pharma companies. This would be an outcome of a) the sizeable generic opportunity (drugs with brand value of USD 80 billion are expected to face generic competition) over the next 4-5 years, b) strong product pipeline of pending ANDAs with high increasing proportion of complex generics and c) market share improvement given the relatively small base (share of leading Indian companies is less than 10 percent in the U.S. generics space). In addition, acquisitions by Indian companies to add technical capabilities and focus on strengthening branded business (albeit on a small scale) are also likely to drive growth going forward as companies feel the need to diversify.

While growth momentum in the domestic formulation industry slowed down in 2012-13 owing to a confluence of reasons (discussed above), ICRA believes that the industry would revert to its long-term growth trajectory in the medium-term as structural growth drivers continue to remain impervious. The growth momentum has picked-up over the past few months and with pricing policy related matters behind us, ICRA expects the industry to revert to a growth of 10- 12 percent in 2013-14. The impact of new DPCO though expected to be limited, could also get offset by volume expansion and efforts of industry participants to take price hike in rest of the portfolio. In Europe, the performance of Indian companies improved in 2012-13 in comparison to the prior year led by primarily new product launches which helped to offset the impact of pricing pressure.

However, given the pace of healthcare reforms and the way competitive landscape is changing in Europe, ICRA believes that the performance of generic companies would remain contingent on new product introductions. As many of the European markets are gradually shifting character from being 'branded generic' to 'un-branded generic' and from being 'physician-influenced' to 'payor-influenced, a relook at business plans also appears to be a common theme across companies. Generics companies are increasingly focusing on expanding presence in relatively underpenetrated markets (i.e. France, Spain & Italy), branded generic markets of East Europe and niche areas like complex generics, OTCs etc. In general, Indian pharma companies generate a relatively lower share of revenues from Europe with profitability also subdued compared to other markets. In addition US generics, emerging markets present one of the most promising growth opportunities for Indian pharmaceutical companies. As growth prospects normalize in developed markets, companies are increasingly focusing on emerging markets through portfolio expansion, alliances or JVs and acquisitions, says ICRA. According to ICRA, given the distinct nature of some of the markets being tapped, managing regulatory hurdles (i.e. delays in receiving approvals in Brazil, healthcare reforms in Russia) and execution however remains the key. Indian companies though have an inherent advantage given their experience with 'branded generics' in India. Amongst new frontiers, evolving generic market in Japan (world's second largest pharmaceutical market with only 23 percent generic penetration) and biosimilars provide alternative growth prospects for Indian companies.

I take this opportunity to invite you to be the part of this historic 6th Edition of Pharmaceutical Leadership Summit & Business Leadership Awards 2013. I hope your presence at the summit will be an enlightened one.

The

changergame

Incredible Pharmaleaders 2013. – " Pushing India's Growth Agenda-" is the theme of the historic edition of Pharmaleaders's 6th Leadersh ip Summi t & Pharmaleaders Business Leadership Awards 2013 to be staged in Mumbai on 27th Year, the much anticipated & awaited prestigious title is attempting to revisit the current state of affairs & the pressure of building brands & m o s t i m p o r t a n t l y , maintaining the sustainable growth record in an era where Government's policy making machine making a difficult task to the thinking process & the strategies to retain market dominance. As Pharma leaders march ahead to host the event, both domestic & international markets have been witnessing a change of approach. The Price war, US FDA Vigilance, FDI & Generics are the key

drivers that will determine the winning combinations.December 2013 in the commercial capital of India, Mumbai. Entering in its 6thIndian markets are far more mature and have given their thumbs down to the controversial Food Security Bill. But the UPA government will do all it takes to indulge in such populist measures even going to the extent of driving the country down the fiscal drain. Fiscal deprivation just adds on to the long list of pitfalls of the UPA government including corruption, apathy, indecision and pseudo secularism. Its time for the people of India to fight back. Otherwise its the middle class and the hapless poor who will pay the price for supporting such a corrupt and inept regime. Pharmaleaders feel the heat when finding the right perspectives as the overwhelming numbers suggest that the Pricing Policy of the Government have taken a toll signaling the death of investments in R & D in the absence of a strong patent regime.

However, the new Drug Prices Control Order (DPCO) 2013 seems to be forcing doctors and patients to turn to substitutes, courtesy a silent protest by chemists across the state. Chemists are unhappy because with the DPCO retail chemists are losing 7% commission while wholesalers, about 3% on each drug sold. Chemists claimed that only 40% of pharma companies in the state have so far agreed to match their margins. In a landmark decision, the DPCO has lowered prices of 348 essential drugs to bring them within the reach of every patient.However, it seems a tough time is looming for patients; examine the many challenges facing the industry and the policy options open to the Indian government to avert an impending crisis in its capacity to continue the production of cheap generics.

The government of India implemented a series of policy measures in the 1970s to achieve self-sufficiency in pharmaceutical production. The first step was to revamp the colonial patent legislation and abandon product patent protection for medicines. Hence, the Patents Act 1970 allowed only process patent protection for pharmaceutical inventions. As a result, Indian companies could produce new medicines which had been introduced in the international market but were not available to needy patients in India. This made possible the production and sale of new medicines at affordable prices.Secondly, the government introduced control measures on foreign ownership under which foreign companies were not allowed to hold more than 50% of equity.Thirdly, the government introduced direct price control on all formulations of about 347 bulk drugs.Fourthly, pharmaceutical multinational corporations (MNCs) were forced to start production of both formulation and bulk drugs in India.Fifthly, public sector production of bulk drugs encouraged the small and medium enterprise (SME) sector to start formulation.Within a span of some 20 years, these policy initiatives cumulatively made India not only self- sufficient but also a net exporter of generic medicines.

THEME

www.pharmaleaders2013.com

INCRED BLE


BILLION DREAMS

Glimpses of the Magic Moments


INCRED BLE


BILLION DREAMS

6th


20132013TM

AnnualPOWER

Pharma Leaders

2013

Pharma Leaders

2013

BRAND


Glimpses of the Magic Moments

POWER

Pharma Leaders

2013

Pharma Leaders

2013

BRAND


INCRED BLE


BILLION DREAMS


Friday, December 27, 2013

2:00PM - 3:00PM Registration, Reception & Networking High Tea

PROGRAM AGENDA : 6th Annual Pharmaceutical Leadership

Summit & Pharmaleaders Business Leadership Awards 2013

Opening Address & Summit Moderation

Market Leader ( Life Sciences).Future Steps ( A Korn/Ferry Company)

Mr. S. Krishnakumar (KK),3:00PM - 3:10PM

Theme & Welcome Address

Chairman & Editor-In-Chief – Pharmaleaders Group

Mr. Satya Brahma

Inaugural Address : The Rise of India as a Healthcare powerhouse in the world

Secretary General, IDMA (Indian Drug Manufacturers Association)

Mr. Daara Patel

Keynote AddressDecoding the success mantra of Indian Pharma Industry in an era of Govt regulations.

Promoter Director,Salus Lifecare Pvt Ltd ,Mr. Kewal Kanda

Keynote Address

Founder Chairman, Dr Batra's Positive Health Clinic Challenges of Globalizing Homeopathic Medicines : A Dr Batra's Case Study

Dr Mukesh Batra,


3:10PM - 3:20PM

3:20PM - 3:40PM

3:40PM - 4:00PM

4:00PM - 4:25PM

AGENDA 6th


20132013TM

Annual

Government's Perspective Regulatory Challenges of Indian Plants. FDA Initiative to curb counterfeit drugs.

Commissioner FDA, Maharashtra, Government of MaharashtraMr.Mahesh Zagade,

The Evolving Profile of the Indian Medical Practioners: Doctors Expectations from the Pharmaceutical Companies – Beyond Gifts & Vacation Sponsorships

Consulting EndocrinologistDr Shasank. R. Joshi

Panel Discussion: Ethics in Medical Pofession

Dr. Chytra V Anand Founder&CEO &

Chief Cosmetic DermatologistKOSMODERMA

ChairpersonDr. Siddharth N. ShahConsulting Physician & DiabetologistEsteemed Panel Members

Dr.Jothydev KesavadevFounder Chairman, Jothydev's Diabetes

Research Centre

Dr. Rashmi Shetty Non-Surgical Aesthetic

Medicine Expert

Dr. Kaushal PandeyCardiac Surgeon

Dr Shashank R JoshiPhysician Endocrinologist &

Dialectologist

Dr. Sudhir VaishnavInterventional Cardiologist

Dr Deepak K JhumaniConsultant in Sexual

Health and Counsellor

Dr. Harish S. Bhende Orthopaedic Surgeon,

Dr Laud Clinic.


4:25PM - 4:40PM

4:40PM - 5:00PM

5:00PM - 5:30PM

Dr. Deepak ChaturvediPhysician Endocrinologist & Dialectologist

Keynote Address

Managing Director, GlaxoSmithKline Pharmaceuticals Ltd

Dr. Hasit Joshipura

6:00PM - 6:25PM Refreshment Break & Networking

FDI in Pharma. FDI policy of the Govt to protect domestic generic (off-patent) firms.

Founder Chairman, Trivitron Group of Companies Dr.GSK Velu

Making of India's Leadership in Medical Innovation : The Real Time Experience

Cardiovascular and Cardiothoracic Surgeon & CMDS,MedantaDr Naresh Trehan

The Changing Face of Indian Skin care Innovations

Cosmetic Dermatologist CEO & Founder, Le'jeune Medspa

Dr. Shuba Dharmana

Cost effective Healthcare through citizens community participation

Founder, Dr Laud Clinic

Prof. Dr. Nandkishore Shamrao Laud

08.00 pm onwards 6th Annual Pharmaceutical Leadership Summit & Business Leadership Award 2013 followed by Cocktail & Gala Dinner.

5:30PM - 5:45PM

6:25PM - 6:35PM

7:00PM - 7:30PM

7:30PM - 7:45PM

7:45PM - 8:00PM

6:35PM - 7:00PM Panel Discussion : The Changing Face of Pharmaleaders

Has the Pharmaceutical Companies failed to impress the doctors on medical education by adopting unethical means?

Managing Director, Health 'N' U Therapeutics Pvt. Ltd Mr. Deepak Naik,

5:45PM - 6:00PM

6th


20132013TM

Annual

Ticket to this event include all panels, forums, networking,high tea, dinner, cocktail, award presentation ceremony & of course cultural extravaganza. For Group Bookings orEnquiry, Please contactOur Event Team At : [email protected]

INCREDIBLE PHARMALEADERS 2013BILLION DREAMS – PUSHING INDIA'S GROWTH AGENDA

stFriday, 27 December 2013, Hotel Hilton, Mumbai Intercontinental, Airport, Mumbai, India

6th ANNUAL PHARMACEUTICAL LEADERSHIP

SUMMIT & BUSINESS LEADERSHIP AWARDS 2013

Summit Secretariat & Registration Desk.Dreamz Activations Unit No. 53, 2nd Floor, Aditya Industrial, Estate, CTS No. 1068 - C, Plot No.444 ( P ), Devrukhkar

Wadi, Chincholi Bunder Road, Malad ( W ), Mumbai - 400 064. Phone: + 91 22 4248 1234 / 4248 1235. Email :

[email protected] / [email protected]

REGISTRATION APPLICATION

Registration Informations: Per Delegate Fees: INR RS 10000 + 12.36 SERVICE TAX

We are pleased to nominate the following participant(s) for the Summit:

Sr : Name : Designation: Email id :

1.______________________________ _______________________ _______________

2.______________________________ _______________________ _______________

3.______________________________ _______________________ _______________

The DD / Cheque No. ________________ for Rs. ________________ towards the delegate fee drawn in favour of

“Dreamz Activations”, payable at Mumbai is enclosed.

Name:________________________________________________Designation :____________

Company:_____________________________________

Address:_______________________________________________________________________________

Telephone:__________________________Fax:_________________________Mobile:_________________

Email:_________________________________________Website:_________________________________

Terms & Conditions

ØA 10% discount for 3 or more delegates Delegate fee non-refundable but change in nomination accepted

ØPre-Registration and Pre-Payment is a must

Ø


REGISTER TODAY

Individual Non-Voting Award Categories


Dr Naresh TrehanFounder Chairman,

Medanta

Prof. Dr. Nandkishore Shamrao LaudFounder, Dr Laud Clinic

Global Indian of the Year 2013

Mr. Satish Ramanlal MehtaCEO & MD,

Emcure Pharmaceuticals Limited

Business Leader of the Decade India's Most Admired Homeopathic Brand 2013

Padma Shri Dr. Viswanathan Mohan Founder & CEO

Dr. Mohan's Diabetes Specialties Centre.

Incredible Medical Expert of the Decade. (Individual Awards by Jury)

Dr Shasank R JoshiConsulting Endocrinologist &

Founder, Joshi Clinic

Dr.Jothydev KesavadevFounder Chairman,

Jothydev's Diabetes Research Centre

Dr. Kaushal PandeyCardiac Surgeon, Jaslok Hospital

Dr. K. Ravindranath

CMD, Global Hospitals Group HelthCare Visionary of the Decade

Individual Non-Voting Award Categories


Mr. D.C. JainChairman, Akums Drugs &

Pharmaceuticals Ltd.

Lifetime Achievement Award 2013

Pioneering Innovation in Stem Cell Banking Award 2013

Emerging Hospital Chain of the Year 2013

Entrepreneur of the year 2013

Dr G.S.K. Velu

CEO & Managing Director

Trivitron Healthcare

Rising Brand of the Year 2013 Transformational Leader of the Decade

Business Leader of the year (Healthcare & IT) 2013

Non-Surgical Aesthetic Medicine Expert 2013

Dr. Rashmi Shetty, CEO & Founder,Ra Skin & Aesthetcs

Mr. Upinder ZutshiCEO & MD, Infinite Computers (I) Ltd.

Dr Mukesh Batra Founder Chairman,

Dr Batra's Positive Health Clinic

INCRED BLE


BILLION DREAMS

6th


20132013TM

Annual

POWER

Pharma Leaders

2013

Pharma Leaders

2013

BRAND

The Emerging Leader

in innovation SKINCARE

get ready to attend asia’s biggest leadership …pharmaleaders2017.com/downloads/6th-annual...6 th...

Documents